Zika Virus

Sophie Masmejan (1) , Didier Musso (2) , Manon Vouga (3, 1) , Leo Pomar (4) , Pradip Dashraath , Milos Stojanov (1) , Alice Panchaud (5, 3) , David Baud (1)

1 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
2 VITROME - Vecteurs - Infections tropicales et méditerranéennes
3 UNIL - Université de Lausanne = University of Lausanne
4 Centre Hospitalier de l'Ouest Guyanais Franck Joly [Saint-Laurent-du-Maroni, Guyane Française]
5 UNIGE - Université de Genève = University of Geneva

Zika virus (ZIKV), a neurotropic single-stranded RNA flavivirus, remains an important cause of congenital infection, fetal microcephaly, and Guillain-Barre syndrome in populations where ZIKV has adapted to a nexus involving the Aedes mosquitoes and humans. To date, outbreaks of ZIKV have occurred in Africa, Southeast Asia, the Pacific islands, the Americas, and the Caribbean. Emerging evidence, however, suggests that the virus also has the potential to cause infections in Europe, where autochtonous transmission of the virus has been identified. This review focuses on evolving ZIKV epidemiology, modes of transmission and host-virus interactions. The clinical manifestations, diagnostic issues relating to cross-reactivity to the dengue flavivirus and concerns surrounding ZIKV infection in pregnancy are discussed. In the last section, current challenges in treatment and prevention are outlined.

Mots clés: Zika; Zika virus; emerging infectious diseases; congenital Zika syndrome; materno-fetal infections; Guillain-Barré syndrome

Domaines: Sciences du Vivant [q-bio]

Sophie Masmejan, Didier Musso, Manon Vouga, Leo Pomar, Pradip Dashraath, et al.. Zika Virus. Pathogens, 2020, 9 (11), ⟨10.3390/pathogens9110898⟩. ⟨hal-03164926⟩